Pathak Surajit, S Sushmitha, Banerjee Antara, Marotta Francesco, Gopinath Madhumala, Murugesan Ramachandran, Zhang Hong, B Bhavani, Girigoswami Agnishwar, Sollano Jose, Sun Xiao-Feng
Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India.
ReGenera Research Group for Aging-Intervention, Milano, Italy and San Babila Clinic, Healthy Aging Unit by Genomics and Biotechnology, Milano, Italy.
Oncotarget. 2017 Nov 16;9(7):7739-7748. doi: 10.18632/oncotarget.22471. eCollection 2018 Jan 26.
Colorectal cancer, fourth leading form of cancer worldwide and is increasing in alarming rate in the developing countries. Treating colorectal cancer has become a big challenge worldwide and several antibody therapies such as bevacizumab, panitumumab and cetuximab are being used with limited success. Moreover, mutation in gene which is linked with the colorectal cancer initiation and progression further interferes with the antibody therapies. Considering median progression free survival and overall survival in account, this review focuses to identify the most efficient antibody therapy in combination with chemotherapy (FOLFOX-4) in mutated colorectal cancer patients. The bevacizumab plus FOLFOX-4 therapy shows about 9.3 months and 8.7 months of progression free survival for wild and mutant type, respectively. The overall survival is about 34.8 months for wild type whereas for the mutant it is inconclusive for the same therapy. In comparison, panitumumab results in better progression-free survival which is about (9.6 months) and overall survival is about (23.9 months) for the wild type and the overall survival is about 15.5 months for the mutant . Cetuximab plus FOLFOX-4 therapy shows about 7.7 months and 5.5 months of progression-free survival for wild type and mutant type, respectively. Thus, panitumumab shows significant improvement in overall survival rate for wild type , validating as a cost effective therapeutic for colorectal cancer therapy. This review depicts that panitumumab along with FOLFOX-4 has a higher response in colorectal cancer patients than the either of the two monoclonal antibodies plus FOLFOX-4.
结直肠癌是全球第四大常见癌症，且在发展中国家正以惊人的速度增长。治疗结直肠癌已成为全球一项重大挑战，目前正在使用几种抗体疗法，如贝伐单抗、帕尼单抗和西妥昔单抗，但成效有限。此外，与结直肠癌发生和进展相关的基因突变进一步干扰了抗体疗法。考虑到无进展生存期和总生存期的中位数，本综述旨在确定在突变型结直肠癌患者中与化疗（FOLFOX-4）联合使用的最有效抗体疗法。贝伐单抗联合FOLFOX-4疗法在野生型和突变型患者中的无进展生存期分别约为9.3个月和8.7个月。野生型患者的总生存期约为34.8个月，而对于突变型患者，相同疗法的总生存期尚无定论。相比之下，帕尼单抗可带来更好的无进展生存期，野生型患者的无进展生存期约为9.6个月，总生存期约为23.9个月，突变型患者的总生存期约为15.5个月。西妥昔单抗联合FOLFOX-4疗法在野生型和突变型患者中的无进展生存期分别约为7.7个月和5.5个月。因此，帕尼单抗在野生型患者的总生存率方面有显著提高，被证实是一种治疗结直肠癌的经济有效的疗法。本综述表明，与两种单克隆抗体之一联合FOLFOX-4相比，帕尼单抗联合FOLFOX-4在结直肠癌患者中的反应更高。
